Acadia Pharmaceuticals Stock Surges Following Positive Regulatory News

Acadia Pharmaceuticals (NASDAQ: ACAD) stock rose by 12.2% as of midday Friday after the European Medicines Agency’s CHMP recommended approval for Daybue in treating Rett syndrome symptoms in Europe, potentially expanding its market beyond the U.S.

By James Brumley, The Motley Fool Fri, June 26, 2026 at 7:37 PM GMT+3 3 min read · Yahoo Finance · June 26, 2026, 16:37 UTC

Acadia Pharmaceuticals Stock Surges Following Positive Regulatory News

Tickers: $ACAD

Topics: Daybue European Medicines Agency (EMA) Rett syndrome stock movement

Read the full article at Yahoo Finance

More World news

CorMedix Announces Acquisition of Heron Therapeutics Assets to Drive Revenue Growth Seeking Alpha · November 12, 2026, 19:20 UTC
Tetra Tech Forecasts FY 2027 Revenue Between $4.425B and $4.625B Amid Backlog Growth Seeking Alpha · November 12, 2026, 19:20 UTC
Donald Trump Jr. Steps Down from Kalshi Advisory Role Due to Conflict of Interest CNBC · November 12, 2026, 19:14 UTC
Centalion Americas Refinances and Upsizes Credit Facility to $3.5 Billion PR Newswire · November 12, 2026, 19:15 UTC
Nvidia Faces Leadership Transition as Jensen Huang Resigns Amid Investigation Seeking Alpha · November 12, 2026, 18:30 UTC
SOLV Energy Reports Record Q3 2026 Results and Raises Full-Year Guidance Motley Fool · November 12, 2026, 19:09 UTC
Clear Secure Reports Strong Q3 Earnings and Raises Full Year Guidance Amid Expansion into Identity Verification CNBC · November 12, 2026, 19:09 UTC
Nectar Launches AI Agent to Automate Influencer Discovery and Outreach TechCrunch · November 12, 2026, 19:11 UTC
Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC